Investor Presentaiton
...have led to Marksans of Today..
Business:
Regulated Markets Focus
Products
FY17
Regulated markets: 741.6 crs
Emerging markets: 32.9 crs
100+
FY21
1313.8 crs
Regulated markets:
Emerging markets: 62.3 crs
~300
Manufacturing
Facilities
Goa: 6 billion capsules and tablets p.a.
UK: 13.6 million bottles p.a.
7.8 million tubes p.a.
5.75 million units p.a.
USA: 5 billion tablets & capsules p.a.
1- Goa
R&D
R&D to sales: 0.6%
Revenue:
767.2 cr.
EBITDA:
44.7 cr.
Goa: 8 billion capsules and tablets p.a.
UK: 2 billion bottles p.a.
1 billion tubes p.a.
1 billion sachets p.a.
USA: 6 billion tablets & capsules p.a.
1 - Goa
2- Navi Mumbai
R&D to sales: 1.4%
Revenue:
1376.2 cr.
EBITDA: 339.6 cr.
Financials
©2021 - Marksans Pharma Limited, All Rights Reserved.
EBITDA %: 5.8%
PAT: 11.3 Cr.
EBITDA%: 17.2%
PAT: 238.5 cr.
19View entire presentation